SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Corcept-Lifyorli Combination Shows Responses in 59% of Ovarian Cancer Patients

Corcept said its combination with Lifyorli produced responses in 59% of patients in the phase 2 BELLA study.

CORT

Related stories